Details of the Drug Combinations

General Information of This Drug (ID: DMYEB5F)

Drug Name

CC-115 DMYEB5F

Synonyms

CC-115 (hydrochloride); CC-115 hydrochloride; 1300118-55-1; SCHEMBL1767621; BCP20709; HY-16962A; AKOS030526389

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
CC-115 + Panobinostat	DCTLH3T	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
CC-115 + Marizomib	DCJVJL6	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01353625) Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.. U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.